Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis

Journal of Affective Disorders

Volumn 122, Issue 1-2, 2010, Pages 1-9

  Smith, L A ^a   Cornelius, V R ^a   Azorin, J M ^b   Perugi, G ^c   Vieta, E ^d   Young, A H ^e   Bowden, C L ^f  

^a Medical Research Matters   (United Kingdom)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c UNIVERSITY OF PISA   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bipolar depression; Efficacy; Meta analysis; Systematic review; Tolerability; Valproate

Indexed keywords

PLACEBO; VALPROATE SEMISODIUM;

ANXIETY; BIPOLAR DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; HUMAN; HYPOMANIA; META ANALYSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; AFFECT; ANTICONVULSANTS; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77649340367     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.10.033     Document Type: Review

References (33)

1. Australian and New Zealand College of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust. NZ J. Psychiatry 38 (2004) 280-305
2. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J. Affect. Disord. 43 (1997) 163-166
3. Bradburn M.J., Deeks J.J., Berlin J.A., and Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat. Med. 26 (2007) 53-77
4. Calabrese J.R., Hirschfeld R.M., Frye M.A., and Reed M.L. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J. Clin. Psychiatry 65 (2004) 1499-1504
5. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 (2005) 1351-1360
6. Calabrese J.R., Kasper S., Johnson G., Tajima O., Vieta E., Yatham L.N., and Young A.H. International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression. J. Clin. Psychiatry 69 (2008) 1632-1646
7. Davis L.L., Bartolucci A., and Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord. 85 (2005) 259-266
8. Geddes J.R., Calabrese J.R., and Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry 194 (2009) 4-9
9. Ghaemi S.N., and Goodwin F.K. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J. Affect. Disord. 65 (2001) 281-287
10. Ghaemi S.N., Gilmer W.S., Goldberg J.F., Zablotsky B., Kemp D.E., Kelley M.E., Bauer A.D., Fleck J., Filkowski M.M., Stan V.A., and Dunn R.T. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J. Clin. Psychiatry 68 (2007) 1840-1844
11. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., and Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 161 (2004) 1537-1547
12. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. (Oxf., England) 17 (2003) 149-173 Discussion 147
13. In: Higgins J.G.S. (Ed). Cochrane Handbook for Systematic Reviews of Interventions (2008), Wiley-Blackwell, Chichester (UK)
14. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. Bmj 327 (2003) 557-560
15. Hirschfeld R.M. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159 (2002) 1-50
16. Hirschfeld R.M., Calabrese J.R., Weissman M.M., Reed M., Davies M.A., Frye M.A., Keck Jr. P.E., Lewis L., McElroy S.L., McNulty J.P., and Wagner K.D. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64 (2003) 53-59
17. Hirschfeld R.M., Cass A.R., Holt D.C., and Carlson C.A. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J. Am. Board of Family Practice/Am. Board Family Practice 18 (2005) 233-239
18. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., and Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002) 530-537
19. Juni P.A.D., and Egger M. Assessing the Quality of Randomised Controlled Trials (2001), BMJ Publishing group
20. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., and Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 593-602
21. Kupka R.W., Altshuler L.L., Nolen W.A., Suppes T., Luckenbaugh D.A., Leverich G.S., Frye M.A., Keck Jr. P.E., McElroy S.L., Grunze H., and Post R.M. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 9 (2007) 531-535
22. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., and Loring D.W. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360 (2009) 1597-1605
23. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., Irwin B., McGivern R.C., Morrison P.J., and Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 77 (2006) 193-198
24. Muzina D., Ganocy S., Khalife S., Gao K., Kemp D., Bachtel M., Colangelo E., Conroy C., Bilali S., and Calabrese J. A Double-blind, Placebo-controlled Study of Divalproex Extended-release in Newly Diagnosed Mood Stabiliser Naive Patients with Acute Bipolar I or II Depression. Presented at the 48th NCDEU Meeting: New Approaches for Mental Health Interventions, Phoenix, Arizona, USA May 27-30 2008 (2008)
25. National Institute for Health and Clinical Excellence. The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. National Clinical Practice Guideline Number 38 (2006)
26. Sachs G., Altshuler L., Ketter T., Suppes T., Rasgon N., Frye M., and Collins M. Divalproex versus Placebo for the Treatment of Biolar Depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology December 9-13, 2001 San Juan, Puerto Rico (2001)
27. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., and Calabrese J.R. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26 (2006) 600-609
28. Thase M.E., Jonas A., Khan A., Bowden C.L., Wu X., McQuade R.D., Carson W.H., Marcus R.N., and Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 28 (2008) 13-20
29. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 (2003) 1079-1088
30. Tomson T., and Battino D. Pregnancy and epilepsy: what should we tell our patients?. J. Neurol. 256 (2009) 856-862
31. Winsberg M.E., DeGolia S.G., Strong C.M., and Ketter T.A.m. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J. Affect. Disord. 67 (2001) 207-212
32. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S.V., Macqueen G., Mclntyre R.S., Sharma V., Beaulieu S., Alda M., Baruch P., Daigneault A., Milev R., Young T.L., Ravindran A., Schaffer A., Connoly M., and Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 8 (2006) 721-739
33. Yusuf S., Wittes J., Probstfield J., and Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Jama 266 (1991) 93-98